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Abstract 
Background & Aims: Neonatal sclerosing cholangitis (NSC) is a severe neonatal-onset 
cholangiopathy commonly leading to liver transplantation (LT) for end-stage liver disease in 
childhood. Liver-biopsy findings histopathologically resemble those in biliary atresia (BA); 
however, in NSC extrahepatic bile ducts are patent, whilst in BA their lumina are obliterated. 
NSC is commonly seen in consanguineous kindreds, suggesting autosomal recessive 
inheritance. 
Methods: From 29 NSC patients (24 families) identified, DNA was available in 24 (21 
families). Thirteen (7 male) patients (12 families) of consanguineous parentage were selected 
for whole exome sequencing. Sequence variants were filtered for homozygosity, 
pathogenicity, minor allele frequency, quality score, and encoded-protein expression pattern. 
Results: Four of 13 patients were homozygous and two were compound heterozygous for 
mutations in DCDC2, encoding doublecortin domain containing 2 (DCDC2), expressed in 
cholangiocyte cilia. Another 11 patients were sequenced: one (with one sibling pair) was 
compound heterozygous for DCDC2 mutations. All mutations were protein-truncating. In 
available liver tissue from patients with DCDC2 mutations, immunostaining for human 
DCDC2 and the ciliary protein acetylated alpha-tubulin (ACALT) showed no expression 
(n=6) and transmission electron microscopy found that cholangiocytes lacked primary cilia 
(n=5). DCDC2 and ACALT were expressed in NSC patients without DCDC2 mutations 
(n=22). Of the DCDC2, one patient died awaiting LT; five came to LT, of whom one died 2 
years later. The other 4 are well. 
Conclusion: Among 24 NSC patients with available DNA, 7 had mutations in DCDC2 (6 of 
19 families). NSC patients in substantial proportion harbour mutations in DCDC2. Their 
disease represents a novel liver-based ciliopathy. 
Lay summary: Neonatal sclerosing cholangitis (NSC) is a rare genetic form of liver disease 
presenting in infancy. Through Next Generation Sequencing we identified mutations in the 
gene encoding for doublecortin domain containing 2 (DCDC2) protein in a group of NSC 
children. DCDC2 is a signalling and structural protein found in primary cilia of 
cholangiocytes. Cholangiocytes are the cells forming the biliary system which is the draining 
system of the liver. 
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Introduction 
Neonatal sclerosing cholangitis (NSC) is a rare form of severe liver disease first reported in 8 
children presenting in early infancy with jaundice, hepatosplenomegaly, pale stools, and high 
serum γ-glutamyltransferase activity (GGT) [1].  Ductular proliferation, moderate portal-tract 
inflammation, and fibrosis were found at liver biopsy.  Percutaneous cholangiography 
confirmed intrahepatic cholangiopathy in all; 2 had earlier undergone laparotomy to exclude 
biliary atresia (BA).  Most developed biliary cirrhosis.  Three patients were born to 
consanguine parents, suggesting recessive inheritance.  The term NSC was first used for high-
GGT neonatal-onset cholangiopathy in another consanguine sibling pair.  Biliary cirrhosis 
required liver transplantation (LT) for survival [2].  A distinct hepatorenal disorder was later 
suggested in 2 siblings with renal disease, high GGT activity, and, on endoscopic retrograde 
cholangiopancreatography (ERCP) and liver biopsy, early-onset changes like those of 
primary sclerosing cholangitis [3].  Cholangiopathy in children has been attributed to immune 
dysregulation (autoimmune sclerosing cholangitis, immunodeficiency or Langerhans cell 
histiocytosis [4]) and to single-gene disorders (deficiency of multidrug associated protein 3 
(MDR3), encoded by ABCB4 [5],  claudin-1 deficiency [6] or Kabuki syndrome [7, 8]); as 
with BA, it also may have multiple different causes [9]. 
The aim of this study was to identify genes mutated in NSC patients seen at King’s College 
Hospital [10].  We describe the clinical and laboratory features, presentation, and disease 
progression of NSC in these patients; the process and results of whole exome sequencing 
(WES) in a subgroup of these patients, with Sanger-sequencing confirmation of candidate-
gene mutations and selective sequencing of candidate genes, when possible, in the remaining 
patients; and the findings within liver and biliary tract on immunohistochemical assessment of 
encoded-protein and comparison-protein expression as well as on ultrastructural study.  
 
Patients and Methods 
Patients 
The diagnosis of NSC was assigned to 29 patients (24 families) whose disorder clinically 
presented during infancy; who had cholestasis with elevated GGT; and in whom 
cholangiopathy was demonstrated on histopathologic study or imaging.  Exclusion criteria 
were evidence of ichthyosis-like skin lesions, extrahepatic abnormalities suggesting Alagille 
syndrome, mutations in ABCB4, or immune dysregulation.  Patients had normal serum 
immunoglobulin values (IgM, IgG, IgA), lacked demonstrable autoantibodies (anti-nuclear, -
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smooth muscle, -liver – kidney microsome, -mitochondrial, -gastric parietal cell), and had 
normal complement levels (C3 / C4). 
Histologic features of cholangiopathy and cholestasis, present in all available specimens (28 
patients), included porto-septal bridging fibrosis, ductular reaction, hepatocellular 
metallothionein deposits, and intralobular bile-pigment accumulations (Figure 1A).  MDR3 
expression was demonstrated immunohistochemically (Figure 1F, inset) in all specimens.  
Radiological features included irregular dilatation and strictures in intrahepatic or 
extrahepatic bile ducts, consistent with a cholangiopathy. 
Stored blood or DNA was available in 24 patients (19 families).  Blood was retrieved for 
WES from the Paediatric Liver Centre biobank for 13 children (12 families) chosen for 
parental consanguinity and availability of DNA suitable for next generation sequencing 
(supplementary information, Table S1).  The remaining 11 patients subsequently underwent 
Sanger sequencing of DCDC2.  Parental or patient consent had previously been obtained for 
research investigation in accordance with institutional guidelines.  Ethical-review committee 
approval for this specific study was obtained, with samples anonymised before use. 
Whole Exome Sequencing 
WES was undertaken using the Roche Nimblegen SeqCap EZ Human Exome Library v2.0, as 
per manufacturer’s protocol.  Initial analysis focused on finding variants distributed in a 
pattern consistent with autosomal-recessive disease inheritance.  WES to permit cataloguing 
of genetic variation in patients followed published protocols [11]. Variants were annotated 
with Variant Effect Predictor and loaded into Gemini software [12]. Variants with minor-
allele frequency > 1% in the 1000 Genome or the Exome Sequencing Project data were 
excluded, as were intergenic variants and variants that were flagged as low quality or 
potential false-positives (quality scores ≤ 30; long homopolymer runs > 5; low quality by 
depth < 5; occurrence within a cluster of single-nucleotide polymorphisms).  Variants of 
interest (see above) were prioritised for biological relevance. 
Sanger sequencing 
Sanger sequencing confirmed variants identified by WES in the first set of patients.  Forward 
and reverse primers were designed and annealing temperatures were set for genes of interest 
(Supplementary information, Table S2).  PCR amplification and sequencing reactions were 
performed using standard protocols [13, 14].  
Histopathologic and ultrastructural studies 
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Archival formalin-fixed, paraffin-embedded liver-biopsy or hepatectomy materials obtained 
for clinical diagnosis were available from 12 of the 13 patients in whom WES was conducted.  
For each patient, tissue sections were cut at 4 µm and stained with haematoxylin-eosin and 
with orcein.  To exclude MDR3 deficiency, parallel sections were immunostained with P311-
26, a monoclonal antibody against MDR3 (Alexis Biochemicals ALX-801-028, Nottingham, 
UK); as a control, parallel sections also were immunostained with M2-lll-6, a monoclonal 
antibody against a homologous bile-canaliculus transporter, human multidrug resistance-
associated protein 2 (Alexis Biochemicals ALX-801-016-C250).  Sections also were 
immunostained using a mouse anti-human DCDC2 monoclonal antibody (Santa Cruz / 
Insight Biotechnology, Wembley, UK; DCDC2 [C4], sc-166051, recognizing C-terminus 
amino-acid residues 331-476; 1:50 dilution, 10 minutes pre-treatment at pH9) with BondMax 
reagents and automated equipment (Leica Microsystems, Milton Keynes, UK).  For 
comparison purposes, hepatobiliary marking for DCDC2 expression in control patients with 
cholestasis (BA, alpha-1-antitrypsin storage disorder, primary sclerosing cholangitis, primary 
biliary cirrhosis, Wilson disease) and in tissue from patients without cholestasis also was 
assessed.  To identify primary cilia, parallel sections were immunostained using a mouse 
monoclonal antibody against acetylated alpha tubulin (ACALT; Sigma-Aldrich (Gillingham, 
Dorset,UK); clone 6-11B-1; 1:6,000 dilution, epitope unmasked by heating at 1000C for 20 
minutes in citrate buffer at pH6). 
Liver material from 5 probands, primarily fixed in paraformaldehyde / glutaraldehyde, either 
at bedside on sampling or on retrieval from -80°C storage, was post-fixed (OsO4) 
and embedded in resin.  Ultrathin sections stained with uranyl acetate / lead citrate were 
evaluated by transmission electron microscopy (TEM), with particular attention to 
cholangiocytes. NSC cases with no DCDC2 mutations, and other cholestatic disorders as 
described above, were used as controls for ultrastructural studies. 
Results 
Demographics 
Twenty-nine children (15 male) from 24 families met inclusion criteria (Table 1 & 
supplementary Table S1).  Parental consanguinity was identified in 16 patients from 12 
families.  Ethnic background was Arab (8 cases), European (11), and South Asian (9), with 
mixed ancestry in 1 child.  Five patients underwent no genetic testing due to lack of DNA. 
Clinical features, disease course, and investigations 
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Most patients presented in their first year of life with a median age of 6 weeks [range, 1-57].  
Patient 19, who was asymptomatic, was identified (raised liver enzymes) aged 4 years 
through family screening.  Patient 28 had been ill for an undefined period when, aged 5 years, 
medical attention was sought due to jaundice and pale stools (Table 1 & supplementary Table 
S1). 
Presenting features were jaundice (27), pale stools (10), hepatomegaly (1), coagulopathy (3), 
gastrointestinal bleeding (3), ascites (2), and splenomegaly (9); some patients manifested 
disease in more than one way.  Median values [and ranges] for serum bilirubin were 111 
µmol/l [5-250], GGT 435 IU/l [148-1,120], alkaline phosphatase 694 IU/l [215-1,200], 
aspartate aminotransferase 179 IU/l [35-482], and albumin 36 g/l [25-48].  ERCP was 
performed in 15 patients and magnetic resonance cholangiopancreatography (MRCP) in one.  
Bile duct changes varied.  Attenuation and irregular strictures of the common bile duct were 
usual, with clubbed and irregular smaller ducts, segmental dilatation and stricturing anywhere 
from common hepatic duct to third-order ducts (Figure 2).  Gallbladders were normal.  No 
patient had cholelithiasis. 
Liver biopsy was performed at KCH in 25 patients.  Liver-biopsy material obtained elsewhere 
from 3 patients was reviewed at KCH.  Patient 29 underwent cholocystojejunostomy aged 18 
years for persistent cholestasis.  Percutaneous transhepatic cholangiography at age 21 years 
showed no obstruction; however, biliary emptying was delayed.  ERCP a year later showed 
papillary stenosis and sphincterotomy was performed, without relief.  In view of persistent 
cholestasis, she underwent LT aged 23 years. 
Extrahepatic disease was recorded in 5 patients.  Three patients (1, 6, and 12) developed renal 
disease.  Patient 1 suffered subarachnoid haemorrhage from a posterior cerebral artery 
aneurysm, which was clipped at age 12 years.  She had previously required splenic 
embolization twice for thrombocytopenia ascribed to portal hypertension and underwent 
splenectomy aged 13 years.  End-stage liver disease developed, as did end-stage renal disease 
requiring dialysis.  She died aged 16 years from a catastrophic oesophageal variceal 
haemorrhage.  Patient 6 developed hepatorenal syndrome type 2 before LT; this resolved, 
with restoration of normal renal function, after LT.  Patient 12 developed end-stage renal 
failure and 2 years after LT underwent a living-related-donor renal transplant aged 4 years.  
Her explanted kidney showed thrombotic microangiopathic changes possibly related to her 
immunosuppression with no cystic changes or features suggestive of nephronophthisis.  
Patient 11 had Prader-Willi syndrome.  Patient 2 developed hepatopulmonary syndrome, fully 
reversed after LT.  No history of intellectual impairment, neurologic dysfunction, 
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sensorineural hearing loss, dysmorphism, osteochondrodysplasia, or other renal disease was 
recorded. 
In all, 16 patients (55%) underwent LT and 2 died of end-stage liver disease whilst awaiting 
LT.  Two patients died after LT, one of unknown causes while in her native country and the 
other from complications of end-stage renal disease.  Liver graft function was unremarkable 
in both.  Overall mortality was 14%.  Patients had a median follow-up of 12 years [range, 2-
34].  
DNA sequencing 
WES in 13 patients identified a total of 998 homozygous or compound-heterozygous variants 
in 310 genes inherited in an autosomal recessive mode.  Genes were categorized by number 
of patients in whom homozygous variations were identified.  In 64 genes 2 or more patients 
had homozygous mutations.  Genes with homozygous variants were filtered further based on 
predicted impact of mutation, prioritising any protein-truncating mutations through the 
introduction of a stop codon directly or downstream via frameshift changes.  Such mutations 
were found in 24 genes.  These were investigated individually, with priority based on liver 
tissue expression recorded in GeneCards (http://www.genecards.org) and Online Mendelian 
Inheritance in Man (OMIM; http://www.omim.org).  Eight genes exhibited homozygous 
variation in 3-patient groups and copy number variant analysis was undertaken. Compound 
heterozygous changes were also investigated in these candidate genes. 
Six (of 13) patients had mutations in DCDC2 (OMIM #605755), encoding doublecortin 
domain containing protein 2 (DCDC2).  Four patients had homozygous changes (2 frameshift, 
2 stop codon) and 2 patients had compound heterozygous changes (2 frameshift, 1 stop 
codon).  All mutations were therefore predicted to be protein truncating (Table 2).  Sanger 
sequencing of DCDC2 in patient 7, an affected sibling of patient 4, found the same mutations 
in exons 4 and 7 as those identified by WES in her sister.  Sanger sequencing of DCDC2 in 
the remaining 10 NSC patients (8 families), numbered 15-24 in the supplementary material 
table, found no mutations.  In the parents of patient 5, Sanger sequencing confirmed 
heterozygous status in the father (c.123_124delGT) and mother (c.890T>A). DNA was not 
available from any other parents.  WES data (not shown) however, showed quite 
convincingly that no patient was hemizygous rather than homozygous for a given DCDC2 
mutation. 
Histopathologic and ultrastructural studies 
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On biopsy at presentation in patients aged eight months or less, varying degrees of portal-tract 
fibrosis without oedema were found.  Numbers of bile-duct profiles were increased in 
interlobular portal tracts, with occasional intraductal bile plugs (Figure 1A).  Persistence of 
the ductal plate was identified in two patients (Patients 3 and 7).  Two patients were biopsied 
at later time points (Patient 7 at nine years and Patient 5 at six years).  Their specimens 
demonstrated paucity of interlobular bile ducts and mild portal tract fibrosis.  At hepatectomy, 
however, portal tracts deficient in portal-venule radicles were broadened by fibrosis.  Biliary-
pattern cirrhosis with parenchymal extinction was found in the periphery.  Small septal bile 
ducts and interlobular bile ducts often were lacking (Figure 1C).  Concentric periductal 
lamellar fibrosis was seen focally, as were disarray and atrophy of ductal 
epithelium.  Hepatocytes, Kupffer cells, and canaliculi contained accumulations of bile 
pigment, particularly in subcapsular regions.  Juxtaseptal hepatocytes contained 
metallothionein deposits.  Large septal bile ducts and hilar bile ducts were preserved, with 
varying dilatation (Figure 1B).  In no specimens were biliary hamartomata (von Meyenburg 
complexes) identified; however, ectasia of large ducts in some patients suggested Caroli-
disease–like changes.  MDR3 was normally expressed in all patients (Figure 1F, inset). 
In control material, DCDC2 was generally expressed by cuboidal cholangiocytes 
(neocholangioles, interlobular bile ducts, small septal bile ducts), but only faint focal marking 
was seen in columnar cholangiocytes (large septal bile ducts, hilar bile ducts, extrahepatic 
biliary tract with gallbladder).  Similar findings were observed in liver material from the NSC 
patients with no DCDC2 mutations (Figure 1E).  However, in patients with proven DCDC2 
mutation, no expression of DCDC2 was found at any site (Figure 1D), consistent with 
absence of the protein.   
Immunostaining for the primary-cilium protein ACALT, conducted to assess presence or 
absence of primary cilia at cholangiocytes, found good expression in small interlobular ducts 
as well as in larger septal and perihilar bile ducts (Figure 3C, inset).  In DCDC2-mutated 
probands, however, ACALT expression was entirely absent in septal and perihilar bile ducts, 
with only very focal and irregular expression in interlobular bile ducts (Figures 3C, 3D).  The 
findings suggested absence of normally constituted primary cilia in association with DCDC2 
mutation.   
In control tissue examined by TEM, primary ciliary structures were identified within 
interlobular bile ducts and neocholangioles (Figure 3B; green arrow).  In the 5 probands with 
tissue available for TEM, lobular cytoplasmic necrosis, dilatation of canalicular lumina with 
amorphous bile, blunting of microvilli, and cytoplasmic blebbing into the canalicular lumen 
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were seen.  Coarsely granular “Byler bile”, tight-junction abnormalities, and 
cholangiocellular primary cilia were not identified (Figure 3A).  
Discussion 
Neonatal sclerosing cholangitis is a rare and severe form of cholangiopathy.  Among our 29 
patients, 4 died in childhood (14%).  More than half (18) developed end-stage liver disease as 
children, with LT performed in 16.  Liver disease like that of NSC has not recurred after LT. 
Utilising WES, we identified mutations in DCDC2 (OMIM #605755) in a subgroup of NSC 
patients.  The encoded protein, DCDC2, is part of the microtubule structure involved in 
ciliary function.  DCDC2 belongs to the doublecortin gene family, the first identified member 
of which is DCX (OMIM #300067).  Mutations in DCX, located at Xq23, are associated with 
subcortical band heterotopia in females and lissencephaly in males [15].  In humans and 
mouse 11 paralogs in the DCX-repeat gene family have been described [16].  Dcdc2 knockout 
mice exhibit multiply disrupted development in memory capacity and phonological 
processing as well as bile duct proliferation and liver fibrosis [17, 18].   
Five different mutations in DCDC2 (3 frameshift, 2 introducing premature stop codons; all 
protein-truncating) were identified in 7 NSC patients, with variants found in exons 1, 4, 5, 6, 
and 7.  The DCDC2 locus contains an antisense transcript, KAAG1 (or RU2AS), on the 
opposite DNA strand.  Six of 7 mutations are predicted to have no effect on this transcript.  
Only 1 of the 7 mutations was present in the antisense transcript.  That our patients’ 
phenotype is the consequence of mutational effects on this other transcript, rather than on that 
of DCDC2, thus seems highly unlikely. 
Patients 2 – 5 and 7 underwent LT (with living-related donation in patient 3) for cholestasis 
and severe pruritus at mean age 14 years [range, 10-15].  Patient 4 died suddenly, of unknown 
causes, 2 years after LT.  Patients 2, 3, and 6 are well, with good graft function.  Median 
follow-up from presentation in these 5 patients is 16 years [range, 6-24].  Patient 1 died 
awaiting LT.  How disease has evolved in patient 5, not followed at KCH, is not known.  
In 2 of the 6 families with NSC and DCDC2 mutation, the parents acknowledged 
consanguinity.  The other 5 patients were all Greek; however, the parents in their 4 families 
came from different parts of Greece, and all sets of Greek parents denied consanguinity.  
Among the patients with DCDC2 mutation and NSC, only patient 7 had liver cysts; two, 
described as “small”, were found in preparation for LT.  Renal ultrasonography during LT 
assessment in 6 patients (1 – 4, 6, 7) found only one cyst, 18 mm in diameter, in the right 
kidney of patient 4.  Renal function was normal at listing for LT in all 6 patients. Patient 2 
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was assessed by cystatin C (0.73 mg/l, n.v. < 1.00 mg/l) and patients 1, 3, 4, 6, and 7 had 
normal age corrected glomerular filtration rate with a median of 103 ml/min/1.73m2  [range, 
92-111).  Whilst awaiting LT, patient 1 subsequently developed end-stage renal disease that 
required dialysis.  To date no further renal disease has appeared in the DCDC2-mutated 
patients. 
In our patients with DCDC2-associated NSC, immunohistochemical study found a complete 
lack of expression of DCDC2.  Features at hepatectomy resembled those of congenital hepatic 
fibrosis centrally and those of sclerosing cholangitis peripherally.  Of interest is that in our 
patients, interlobular and small septal bile ducts (normally lined by cuboidal cholangiocytes, 
which express DCDC2 uniformly and well) first proliferated and then were lost, whilst bile 
ducts in larger septa and at the hilum (normally lined by columnar cholangiocytes, which 
express DCDC2 only weakly and focally) were preserved.  Furthermore, some patients, at 
hepatectomy, exhibited changes that suggested the ductal plate malformation. Models of 
DCDC2 function that accommodate these observations remain to be developed.  Studies of 
ACALT expression identified parallel loss of both ACALT and DCDC2 expression in 
DCDC2-mutated patients but not in other NSC patients.  On ultrastructural study, 
cholangiocytes lacked primary cilia, unlike cholangiocytes in other cholestatic disorders with 
patent biliary-tract lumina[19, 20].  These findings indicate that primary cilia fail to develop 
normally when biallelic protein-truncating mutation in DCDC2 is present.  How loss of 
ciliary integrity predisposes to inflammation and cholestasis, with the phenotype of neonatal-
onset cholangiopathy, is at present unclear [21].  We suggest that the absence of DCDC2 may 
be implicated either in the formation of “cytotoxic” bile or in dysregulation of the 
cholangiocyte’s homeostatic mechanisms, perhaps via Wnt signalling [17].  
Cilia are structures enclosed by the plasma membrane of eukaryotic cells.  They are divided 
into motile cilia such as those of respiratory and genital-tract mucosa and primary cilia (also 
known as sensory cilia) such as those of cholangiocytes [22].  Specialised cilia also exist, 
such as the kinocilia of neuroepithelium (see below).  Each primary cilium consists of a 
microtubule-based axoneme and a basal body – a centriole-based microtubule centre from 
which the axoneme is derived.  Primary cilia, when compared to motile cilia, have the basic 
structure of the 9+0 microtubule arrangement.  However, they lack the inner and outer dynein 
arms and radial spokes of motile cilia, and consequently are non-motile.  
Cholangiocyte cilia were first identified in mice in 1963 [23].  Their main function, through 
utilization of different sensory molecules, is threefold.  Firstly, they can detect alterations in 
bile flow in the biliary-tract lumen via the receptors polycystin 1 & 2; changes in bile flow 
cause cilia to bend.  This stimulus is transduced by polycystins, which form a functional 
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complex that allows calcium ions to enter the cholangiocyte, affecting its function.  Secondly, 
they sense bile composition via purinoreceptors such as P2Y and via interactions with the 
small extracellular vesicles known as exosomes.  P2Y receptors, which are expressed at the 
cholangiocyte apical membrane and on cilia, are stimulated by specific nucleotide 
concentrations in bile.  Their activation influences cell proliferation and secretion.  Exosomes 
are involved in intercellular communication.  They attach themselves to cholangiocyte cilia; 
this attachment affects the extracellular signal-regulated kinase signalling pathway and 
influences cell proliferation [24, 25].  Thirdly, cilia act as osmotic sensors.  As bile traverses 
the biliary tract, its osmolality alters due to absorption of bile acids and glucose, or to 
secretion of bicarbonate ions and water.  Transient receptor potential vallinoid type 4 
channels regulate intracellular ionised-calcium concentrations in response to changes in 
osmolality and biliary secretion, with increased cholangiocyte proliferation [26]. 
DCDC2 has been identified as a candidate gene for dyslexia [27].  DCDC2 is highly 
expressed in the central nervous system throughout foetal and adult life.  It is also present in 
other organs, including the liver.  DCDC2 contains two doublecortin domains, previously 
described in DCX.  These domains are microtubule-binding modifiers.  Microtubules are 
involved in cytoskeletal structure, cell movement and division, and intracellular transport.  
They are a key component of the internal structure of cilia.  Microtubule-associated proteins 
(MAPs) have a regulatory role mediated via binding to microtubules in a nucleotide-
independent process [28].  DCDC2, a known MAP, has the potential to interfere with tubulin 
binding and microtubule polymerisation, and accordingly with development of normal ciliary 
structure [28], as suggested by the lack of ACALT in our DCDC2-mutated patients. Ciliary 
proteins are synthesized in the cytoplasm and endoplasmic reticulum and transported within 
the cilium via the intraflagellary transport system, which is important in multiple ciliary 
functions.  This system, composed of 20 proteins, relies on kinesin-2 or dyneine 2/1b.  It 
operates along microtubules.  MAPs such as DCDC2 affect its operation [29].  DCDC2, as a 
MAP, is localised at the ciliary axoneme, where it interacts with both the sonic hedgehog and 
the Wnt signalling pathways [17, 29-31]. 
Disorders associated with variants in DCDC2 have been described.  A homozygous point 
mutation in DCDC2 (c.1271A>C, p.Gln424Pro) was reported in a Tunisian family with non-
syndromic autosomal recessive hearing loss [10].  Immunofluorescence studies in rat inner 
ear neuroepithelial tissue found that Dcdc2 localized to the primary cilia of nonsensory 
supporting cells and the kinocilia of sensory hair cells (a type of cilium on the apex of hair 
cells located in the sensory epithelium of the vertebrate inner ear), with increased density 
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toward the tip.  They also demonstrated that DCDC2 mutation could deregulate kinociliary 
axoneme length and stability with consequent loss of cell function[10]. 
Nephronophthisis-related ciliopathies (NPHP-RC) are associated with mutations in a variety 
of genes [32-39].  A recent study of 100 consanguine patients with NPHP-RC identified a 
homozygous truncating mutation in DCDC2 (the same as that in our patient 1) in a single 
patient who also had liver disease.  High-throughput exon sequencing of DNA from another 
800 NPHP-RC families in the study found compound heterozygosity for two mutations in 
DCDC2, a frameshift mutation (the same as that in our patient 6) and a splice site mutation 
(c.349-2A>G), in a single patient with hepatic fibrosis but no renal disease up to age of 9 
years.  Whilst no specific liver phenotype-genotype correlations were found in the patients 
studied, hepatic portal fibrosis and bile duct proliferation were documented in Dcdc2 
knockout mice; in addition, interaction between DCDC2 and Wnt signaling was confirmed in 
IMCD3 and NIH3T3 cell culture, as was localisation of DCDC2 in the ciliary axoneme and 
mitotic spindle fibres [17].  
Hepatorenal fibrocystic diseases, commonly known as ciliopathies, include autosomal-
dominant and -recessive polycystic kidney diseases [40, 41] and Joubert [42], Jeune [43], 
Bardet-Biedl [44], Meckel-Gruber [45], and oro-facial-digital syndromes [46].  Liver 
manifestations have been described in congenital hepatic fibrosis, Caroli disease, Jeune and 
Caroli syndromes [43, 47, 48], and polycystic liver disease [49], with gene mutations 
confirmed in a proportion of affected patients [50].  Based on our data, a subset of NSC 
should be included among the ciliopathies.  
In our patients with DCDC2 mutations, only one manifested chronic renal disease, although 
another had a small renal cyst and another suffered transient renal impairment during an 
episode of liver failure.  Other features of hepatorenal ciliopathies, such as 
osteochondrodysplasia or multiorgan cystic change, were not observed, and central nervous 
system dysfunction or hearing loss – potential concerns, given the pattern of DCDC2 
expression in early life and observations noted above – were not recognised.  Our 
identification of DCDC2 mutations in NSC patients, mostly without renal involvement, 
suggests a distinct type of ciliopathy.   
Of particular interest in DCDC2 deficiency is that biliary-tract inflammation, with scarring 
and cholestasis, predominates clinically. This is not the case in other hepatorenal ciliopathies.  
The predominance of liver disease over kidney disease in patients with mutations in DCDC2 
highlights differences in the function of primary cilia between the two organs. The 
mechanisms underlying these differences remain to be determined.  Stimuli generated by 
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alterations of bile composition in the proximal biliary tract, and of urine composition in 
tubuloglomerular structures, could potentially direct different microtubular responses, with 
organ-specific, distinct phenotypes, such as that described in our probands.  In the liver, we 
can only speculate on whether impairment of DCDC2-mediated function alters bile 
composition, making bile more damaging, or lowers cholangiocyte defences against normal 
bile.  However, study of bile-mediated injury pathways could improve our understanding of 
NSC as well as of other early onset cholangiopathies, such as biliary atresia (in which indeed 
ciliary abnormalities are described)[19, 20].  We anticipate that study of DCDC2 function and 
dysfunction will provide insights into cholangiocyte biology and regulation of normal bile 
flow.  
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Fig. 1. Liver biopsy histology and immunohistochemistry in NSC patients with and 
without mutations in DCDC2. Liver biopsy at 4 months from an NSC patient with DCDC2 
mutations (Patient 6) showing expansion of portal areas with ductal bile plugs (arrow) and 
ductular reaction ((A), H&E, magnification 100x. Calibration bar = 100 micrometres). 
Variable ectasia of peri-hilar bile ducts in a hepatectomy specimen from an NSC patient with 
DCDC2 mutations ((B), Patient 4, H&E, magnification 20x. Calibration bar = 500 
micrometres). In the periphery of a hepatectomy specimen from an NSC patient with DCDC2 
mutations, cytokeratin 7 (CK7) immunostaining demonstrates a ductular reaction, but no bile 
ducts are detected in portal areas broadened by fibrosis (arrow). Aberrant expression of CK7 
is seen within the lobule, indicating chronic cholestasis ((C), Patient 4, magnification 40x. 
Calibration bar = 200 micrometres). DCDC2 immunostaining in NSC patients with DCDC2 
mutations demonstrated lack of expression in large peri-hilar bile ducts as well as small 
interlobular bile ducts ((D), main image from Patient 4, absence of DCDC2 immunostaining 
in peri-hilar bile ducts, magnification 20x. Calibration bar = 500 micrometres. Inset from 
Patient 5, liver biopsy at 9 weeks, absence of DCDC2 immunostaining in interlobular bile 
ducts, magnification 100x. Calibration bar = 100 micrometres). A hepatectomy specimen 
from an NSC patient with no DCDC2 mutations shows weak and focal DCDC2 staining in 
large peri-hilar bile ducts (long arrow) and strong diffuse staining in neoductules (short 
arrow) ((E), Patient 12, magnification 40x. Calibration bar = 200 micrometres). Strong 
cytoplasmic and apical biliary epithelial expression of DCDC2 is seen within interlobular bile 
ducts from an NSC patient without DCDC2 mutations ((F), main image, Patient 17, liver 
biopsy at 35 weeks, DCDC2 immunostaining, magnification 200x. Calibration bar = 50 
micrometres). Multidrug resistance protein 3 immunostaining demonstrated canalicular 
expression in NSC patients with DCDC2 mutations (inset, Patient 3, liver biopsy at 8 weeks, 
magnification 200x. Calibration bar = 50 micrometres). 
 
 
 
Fig. 2. Magnetic resonance cholangiography image from patient 25, aged 10 months, 
demonstrating intrahepatic cholangiopathy with bile-duct irregularity and atypical 
smooth extrahepatic ductal dilatation. 
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Fig. 3. Ultrastructural studies and immunohistochemistry for ACALT in liver tissue in 
NSC patients with and without mutations in DCDC2. On ultrastructural study, 
cholangiocyte injury accompanies lack of identifiable primary cilia in patients with NSC and 
DCDC2 mutation (A and B). Acetylated alpha-tubulin (ACALT) expression at 
cholangiocytes is lacking in such patients and is present in NSC patients without DCDC2 
mutation (C and D). (A). Transmission electron micrograph, interlobular bile duct, with 
luminal dilatation, loss of microvilli, intraluminal debris, and apical blebbing of 
cholangiocyte cytoplasm. No primary cilium is apparent. Liver biopsy, age 8 months, Patient 
2. Osmium tetroxide / uranyl acetate / lead citrate, original magnification 2,600x; enlarged to 
facilitate comparison with principal image B (note similar dimensions of mitochondria in 
both). (B). Transmission electron micrograph, interlobular bile duct, with compact lumen, 
usual complement of microvilli, unremarkable cholangiocyte cytoplasm, and transversely 
sectioned primary cilia, with usual internal architecture (arrow; enlarged, also with indicating 
arrow, inset). Hepatectomy specimen, age 12 years, Wilson-disease patient without known 
cholangiopathy. Osmium tetroxide / uranyl acetate / lead citrate, original magnification, 
principal image, 9,200x. (C) ACALT immunostaining in DCDC2 patients demonstrated 
absent or very focal expression (arrow, main image) in interlobular bile ducts (Patient 4, 
hepatectomy, magnification 400x, calibration bar = 20 micrometres). By contrast, NSC 
patients without DCDC2 mutations demonstrated strong apical ACALT expression by 
cholangiocyte epithelium in bile ducts of all sizes (inset image C, interlobular bile duct in 
hepatectomy specimen, Patient 14, magnification 400x, calibration bar = 20 micrometres). 
(D) ACALT expression was not demonstrable in septal or peri-hilar bile ducts in NSC 
patients with DCDC2 mutations (large septal bile duct from hepatectomy specimen, Patient 4, 
magnification 200x, calibration bar = 20 micrometres).     
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Patient Gender/Origin/ 
Consanguinity 
Age at 
presentation 
Presenting 
symptoms 
GGT 
(IU/L) 
ERCP/MRCP 
(intrahepatic 
cholangiopathy) 
Liver histology LT/age at 
LT 
Follow 
up 
1 F/Asian/Yes 20 weeks 
Jaundice, pale 
stools, 
abnormal LFTs 
247 Yes/No (+) N/a No/listed 
Died at 
16 years 
2 
F/Caucasian 
(GR)/No 21 weeks 
Jaundice, GI 
bleeding, 
ascites, 
splenomegaly 
447 Yes 
Liver biopsy at 8 months. Porto-
portal bridging fibrosis. Ductular 
reaction with ductal bile plugs. 
Giant cell change of hepatocytes is 
not a significant feature. 
Hepatectomy specimen at 10 years: 
Biliary pattern cirrhosis. Peripheral 
ductopaenia. Cholestasis. Copper 
binding protein deposition. 
Yes 
10 years 
12 years 
3 M/Arabic/Yes 6 weeks 
Jaundice, GI 
bleeding 
711 N/a 
Liver biopsy at 8 weeks. Ductal 
plate malformation. Small calibre 
portal vein radicles. Ductal bile 
plugs. Hepatocellular cholestasis. 
Giant cell change of hepatocytes is 
not a significant feature. 
Hepatectomy specimen at 14 years: 
Biliary pattern cirrhosis. Peripheral 
ductopaenia. Cholestasis. Copper 
binding protein deposition. 
Yes 
14 years 
16 years 
4 
F/Caucasian 
(GR)/No 4 weeks 
Jaundice, 
splenomegaly 
210 
Yes 
 
Hepatectomy at 15 years. Porto-
portal bridging fibrosis and partial 
nodularity. Peripheral ductopaenia. 
Ectasia and cystic dilatation of 
perihilar bile ducts.   
Yes 
15 years 
Died at 
17 years 
5 
M/Caucasian 
(GR)/No 6 weeks 
Jaundice, 
splenomegaly 
962 Yes 
Liver biopsy at 9 weeks: Porto-
portal bridging fibrosis. Ductular 
proliferation with cholangiopathic 
features. Canalicular and 
hepatocellular cholestasis. Giant 
cell change of hepatocytes is not a 
significant feature. 
Liver biopsy at 6 years. Mild 
fibrosis of portal tracts. Focal 
interlobular bile duct loss and 
cholangiopathic features in 
remaining bile ducts. Features of 
chronic cholestasis. 
No 6 years 
6 
M/Caucasian 
(GR)/No 
7 weeks 
Jaundice, pale 
stools, 
hepatomegaly, 
splenomegaly 
365 Yes/No (+) 
Liver biopsy at 4 months. Porto-
portal bridging fibrosis. Ductular 
proliferation and ductal bile plugs. 
Canalicular cholestasis. Giant cell 
change of hepatocytes is not a 
significant feature. 
Hepatectomy: Biliary pattern 
cirrhosis. Peripheral ductopaenia. 
Ectasia and cystic dilatation of 
perihilar bile ducts. Cholestasis. 
Abundant copper binding protein 
deposition. 
Yes 
15 years 
18 years 
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Patient Gender/Origin/ 
Consanguinity 
Age at 
presentation 
Presenting 
symptoms 
GGT 
(IU/L) 
ERCP/MRCP 
(intrahepatic 
cholangiopathy) 
Liver histology LT/age at 
LT 
Follow 
up 
7          
(sibling 
of 4) 
F/Caucasian 
(GR)/No 1 week Jaundice 196 Yes 
Liver biopsy at 10 weeks. Ductal 
plate malformation. Ductal bile 
plugs. Giant cell change of 
hepatocytes is not seen. 
Liver biopsy at 9 years of age. Mild 
portal fibrosis. Interlobular portal 
tract ductopaenia. Features of 
chronic cholestasis with rosette 
formation in lobules. 
Hepatectomy at 14 years. Biliary 
pattern cirrhosis with peripheral 
ductopaenia. Ectasia and cystic 
dilatation of perihilar bile ducts. 
Cholestasis. Abundant deposition 
of copper binding protein. 
Yes 
14 years 
24 years  
Table 1: Demographical, biochemical, radiological and histological data on NSC 
patients with DCDC2 mutations. MDR3/MRP2 immunostaining was present in liver 
tissue, where available. M, male; F, female; ERCP, Endoscopic retrograde 
cholangiopancreatography; MRCP, Magnetic resonance cholangiopancreatography; 
GI, gastrointestinal; GGT, γ-Glutamyltransferase; GR, Greek; MDR3, multi drug 
resistance protein 3; MRP2, multidrug resistance associated protein 2; LT, liver 
transplantation; NSC, neonatal sclerosing cholangitis; LFTs, liver function tests. 
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Patient 
number Exon Number Zygosity 
Nucleotide 
change Amino acid change 
1 Exon 5 Homozygous c.649A>T p.(Lys217*) 
2 Exon 7 Homozygous c.890T>A p.(Leu297*) 
3 Exon 6 Homozygous c.757insG p.(Ser253Argfs*4) 
4 and 7 
Exon 4 Heterozygous c.529dupA p.(Ile177Asnfs*20) 
Exon 7 Heterozygous c.890T>A p.(Leu297*) 
5 
Exon 1 Heterozygous c.123_124delGT p.(Ser42Glnfs*72) 
Exon 7 Heterozygous c.890T>A p.(Leu297*) 
6 Exon 1 Homozygous c.123_124delGT p.(Ser42Glnfs*72) 
Table 2: Mutations in DCDC2 identified by WES and confirmed by Sanger sequencing. 
Mutations are described based on NM_001195610 
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